Maxona Pharmaceuticals
Pharmaceuticals, 300 Village Dr Apt 719, Malvern, Pennsylvania, 19406, United States, 1-10 Employees
Phone Number: 48********
Who is MAXONA PHARMACEUTICALS
MAXONA Pharmaceuticals, Inc. is a privately held, clinical stage, specialty pharmaceutical company focused on the development and commercialization of a portfolio of novel therapeutics fo...
Read More
-
Headquarters: 300 Village Dr Apt 719, Malvern, Pennsylvania, 19406, United States
-
Date Founded: 2015
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Shawn Fatholahi
Email
Phone
Industry: Pharmaceuticals
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from MAXONA PHARMACEUTICALS
MAXONA Pharmaceuticals Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding MAXONA Pharmaceuticals
Answer: MAXONA Pharmaceuticals's headquarters are located at 300 Village Dr Apt 719, Malvern, Pennsylvania, 19406, United States
Answer: MAXONA Pharmaceuticals's phone number is 48********
Answer: MAXONA Pharmaceuticals's official website is https://maxonapharm.com
Answer: MAXONA Pharmaceuticals's revenue is $1 Million to $5 Million
Answer: MAXONA Pharmaceuticals's SIC: 2834
Answer: MAXONA Pharmaceuticals has 1-10 employees
Answer: MAXONA Pharmaceuticals is in Pharmaceuticals
Answer: MAXONA Pharmaceuticals contact info: Phone number: 48******** Website: https://maxonapharm.com
Answer: MAXONA Pharmaceuticals, Inc. is a privately held, clinical stage, specialty pharmaceutical company focused on the development and commercialization of a portfolio of novel therapeutics for the treatment of pain in the United States. MAXONA is developing MAX-001 as the first novel therapeutic alternative to opioids and NSAIDs for the treatment of pain. While the U.S. is currently experiencing an opioid abuse epidemic, there has been very limited innovation to address the needs of millions of Americans suffering from acute and chronic pain. Hence, there is a significant need for safe and efficacious alternative analgesics. MAX-001 is an ex-US marketed non-opioid, non-NSAID analgesic New Molecular Entity which aims to fundamentally address the short-comings of existing therapies. MAXONA has assembled a highly experienced and well recognized management team with a proven record of successfully developing and commercializing effective therapeutics. We are committed to developing novel therapies for treating pain...without compromise.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month